Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 2
Sponsor overview
MacroGenics
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03729596 | https://clinicaltrials.gov/study/NCT05551117
Assets
Linked programs
- vobramitamab duocarmazine: Registry Stop Signal (4/5)
- vobramitamab duocarmazine 2.0 mg (Arm A): Registry Stop Signal (4/5)